{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:36:52Z","timestamp":1790206612262,"version":"4.1.0"},"reference-count":43,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004761","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2019JJ50932"],"award-info":[{"award-number":["2019JJ50932"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81803035"],"award-info":[{"award-number":["81803035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81703036"],"award-info":[{"award-number":["81703036"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81572946"],"award-info":[{"award-number":["81572946"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Hospital Management Research Foundation of Xiangya Hospital","award":["2016GL21"],"award-info":[{"award-number":["2016GL21"]}]},{"name":"Clinical Big Data System Construction Project of Central South University","award":["46"],"award-info":[{"award-number":["46"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n               <jats:title>Purpose<\/jats:title>\n               <jats:p>Renin-angiotensin system blockers (RASBs), which include angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-2 receptor 1 blockers (ARBs), have been reported to be associated with lung cancer metastasis, radiotherapy and chemotherapy. Until now, very limited clinical data for RASBs\u2019 diagnostic and prognostic effects has existed for lung cancer chemotherapy in Chinese patients.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n               <jats:title>Methods<\/jats:title>\n               <jats:p>There were a total of 678 lung cancer patients with hypertension, of which 461 (68%) were in the non-RASBs group and 217 (32%) were in the RASBs group. Patients\u2019 gender, age, smoking status, histologic differentiation, tumor size, pathological grade, lymph node metastasis, pathological stage and progression-free survival (PFS) were retrospectively analyzed between these two groups. The clinical effects of ACEIs and ARBs in lung cancer patients were compared via t tests, and <jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup> test, and potential prognostic factors for progression-free survival (PFS) were evaluated by Kaplan\u2013Meier analysis.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n               <jats:title>Results<\/jats:title>\n               <jats:p>Significant differences were observed in lymph node metastasis between the RASBs and non-RASBs groups. The RASBs group (62.8% vs 71.7%, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.037) and ARBs group (60.0% vs 71.7%, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.030) had lower lymph node metastasis, and patients with RASBs had a lower pathological stage than those in non-RASBs groups (67.1% vs 77.4%, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.044 ). The PFS of the RASBs (10.7 vs. 6.7 months, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.040) and ACEIs (12.9 vs 6.7 months, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.021) groups were longer than that of the non-RASBs group, while no statistical difference was shown between the ACEIs and ARBs groups. Moreover, the significant results of PFS were further confirmed in pathological stage III\u2013IV patients. In the non-RASB group, 55% of patients took calcium channel blockers (CCBs), and the ACEIs group have a significantly longer PFS compared to the non-CCBs group (6.4 vs 12.9 months, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.036).<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n               <jats:title>Conclusion<\/jats:title>\n               <jats:p>In this study, we showed that the use of RASBs is a positive factor for pathological stage and prognosis of lung cancer patients. Therefore, it is necessary to actively evaluate medical history, especially the use of anti-hypertension medication, in patients with lung cancer and reflect medical history in the treatment and management plans of these patients.<\/jats:p>\n            <\/jats:sec>","DOI":"10.7717\/peerj.8188","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T08:56:26Z","timestamp":1575968186000},"page":"e8188","source":"Crossref","is-referenced-by-count":21,"title":["Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension"],"prefix":"10.7717","volume":"7","author":[{"given":"Jie","family":"Wei","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanli","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanliang","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4443","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"key":"10.7717\/peerj.8188\/ref-1","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/HJH.0b013e328344a7de","article-title":"Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals","volume":"29","author":"ARBT\u00a0Collaboration","year":"2011","journal-title":"Journal of Hypertension"},{"key":"10.7717\/peerj.8188\/ref-2","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1001\/jama.2012.5521","article-title":"Benefits and harms of CT screening for lung cancer: a systematic review","volume":"307","author":"Bach","year":"2012","journal-title":"Journal of the American Medical Association"},{"key":"10.7717\/peerj.8188\/ref-3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","article-title":"Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324, 168 participants from randomised trials","volume":"12","author":"Bangalore","year":"2011","journal-title":"The Lancet Oncology"},{"key":"10.7717\/peerj.8188\/ref-4","doi-asserted-by":"publisher","first-page":"e2697","DOI":"10.1136\/bmj.e2697","article-title":"Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database","volume":"344","author":"Bhaskaran","year":"2012","journal-title":"BMJ"},{"key":"10.7717\/peerj.8188\/ref-5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/sj.thj.6200571","article-title":"Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy","volume":"5","author":"Buchler","year":"2005","journal-title":"Journal of Hematology"},{"key":"10.7717\/peerj.8188\/ref-6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.canlet.2012.10.006","article-title":"Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer","volume":"328","author":"Chen","year":"2013","journal-title":"Cancer Letters"},{"issue":"8","key":"10.7717\/peerj.8188\/ref-7","doi-asserted-by":"publisher","first-page":"dju164","DOI":"10.1093\/jnci\/dju164","article-title":"Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25","volume":"106","author":"Cheung","year":"2014","journal-title":"Journal of the National Cancer Institute"},{"key":"10.7717\/peerj.8188\/ref-8","doi-asserted-by":"publisher","first-page":"k4337","DOI":"10.1136\/bmj.k4337","article-title":"Angiotensin converting enzyme inhibitors and lung cancer","volume":"363","author":"Cronin-Fenton","year":"2018","journal-title":"BMJ"},{"key":"10.7717\/peerj.8188\/ref-9","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1093\/aje\/kwz106","article-title":"Use of antihypertensive medications and survival of breast, colorectal, lung, or stomach cancer","volume":"188","author":"Cui","year":"2019","journal-title":"American Journal of Epidemiology"},{"key":"10.7717\/peerj.8188\/ref-10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.7717\/peerj.8188\/ref-11","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.1073\/pnas.1804000116","article-title":"Aspirin-triggered proresolving mediators stimulate resolution in cancer","volume":"116","author":"Gilligan","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.7717\/peerj.8188\/ref-12","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.12659\/msm.896933","article-title":"Up-regulation of angiotensin-converting enzyme (ACE) enhances cell proliferation and predicts poor prognosis in laryngeal cancer","volume":"22","author":"Han","year":"2016","journal-title":"Medical Science Monitor"},{"key":"10.7717\/peerj.8188\/ref-13","doi-asserted-by":"publisher","first-page":"44877","DOI":"10.1038\/srep44877","article-title":"Hypertension and breast cancer risk: a systematic review and meta-analysis","volume":"7","author":"Han","year":"2017","journal-title":"Scientific Reports"},{"key":"10.7717\/peerj.8188\/ref-14","doi-asserted-by":"publisher","first-page":"k4209","DOI":"10.1136\/bmj.k4209","article-title":"Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study","volume":"363","author":"Hicks","year":"2018","journal-title":"BMJ"},{"key":"10.7717\/peerj.8188\/ref-15","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.amjcard.2010.11.026","article-title":"Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension","volume":"107","author":"Huang","year":"2011","journal-title":"American Journal of Cardiology"},{"key":"10.7717\/peerj.8188\/ref-16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","article-title":"Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?","volume":"352","author":"Lever","year":"1998","journal-title":"Lancet"},{"key":"10.7717\/peerj.8188\/ref-17","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/aje\/kwg179","article-title":"Blood pressure, smoking, and the incidence of lung cancer in hypertensive men in North Karelia, Finland","volume":"158","author":"Lindgren","year":"2003","journal-title":"American Journal of Epidemiology"},{"key":"10.7717\/peerj.8188\/ref-18","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1634\/theoncologist.2019-IO-S1-s02","article-title":"Retrospect and prospect for lung cancer in China: clinical advances of immune checkpoint inhibitors","volume":"24","author":"Lu","year":"2019","journal-title":"Oncologist"},{"key":"10.7717\/peerj.8188\/ref-19","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.7150\/ijbs.27710","article-title":"Effect of RIF1 on response of non-small-cell lung cancer patients to platinum-based chemotherapy by regulating MYC signaling pathway","volume":"14","author":"Mei","year":"2018","journal-title":"International Journal of Biological Sciences"},{"key":"10.7717\/peerj.8188\/ref-20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cllc.2016.07.008","article-title":"Effect of angiotensin system inhibitors on survival in patients receiving chemotherapy for advanced non-small-cell lung cancer","volume":"18","author":"Menter","year":"2017","journal-title":"Clinical Lung Cancer"},{"key":"10.7717\/peerj.8188\/ref-21","doi-asserted-by":"publisher","first-page":"21359","DOI":"10.1038\/srep21359","article-title":"Impact of angiotensin i-converting enzyme inhibitors and angiotensin II type-1 receptor blockers on survival of patients with NSCLC","volume":"6","author":"Miao","year":"2016","journal-title":"Scientific Reports"},{"key":"10.7717\/peerj.8188\/ref-22","volume-title":"The 8th edition of the AJCC cancer staging manual","author":"Morrow","year":"2017"},{"key":"10.7717\/peerj.8188\/ref-23","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.ejso.2018.05.012","article-title":"Association between perioperative beta blocker use and cancer survival following surgical resection","volume":"44","author":"Musselman","year":"2018","journal-title":"European Journal of Surgical Oncology"},{"key":"10.7717\/peerj.8188\/ref-24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.lungcan.2013.01.021","article-title":"Genetic polymorphisms of TERT and CLPTM1L and risk of lung cancer\u2014a case-control study in a Chinese population","volume":"80","author":"Myneni","year":"2013","journal-title":"Lung Cancer"},{"key":"10.7717\/peerj.8188\/ref-25","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/cam4.701","article-title":"Retrospective analysis of bevacizumab-induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer","volume":"5","author":"Nakaya","year":"2016","journal-title":"Cancer Medicine"},{"key":"10.7717\/peerj.8188\/ref-26","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jaad.2017.11.042","article-title":"Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark","volume":"78","author":"Pedersen","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.7717\/peerj.8188\/ref-27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aan5616","article-title":"Targeting the renin-angiotensin system to improve cancer treatment: implications for immunotherapy","volume":"9","author":"Pinter","year":"2017","journal-title":"Science Translational Medicine"},{"key":"10.7717\/peerj.8188\/ref-28","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1097\/HJH.0b013e3283621ea3","article-title":"Angiotensin receptor blockers: are they related to lung cancer?","volume":"31","author":"Rao","year":"2013","journal-title":"Journal of Hypertension"},{"key":"10.7717\/peerj.8188\/ref-29","doi-asserted-by":"publisher","first-page":"7103","DOI":"10.2174\/13816128113199990508","article-title":"The renin-angiotensin system as a target of novel anticancer therapy","volume":"19","author":"Regulska","year":"2013","journal-title":"Current Pharmaceutical Design"},{"key":"10.7717\/peerj.8188\/ref-30","doi-asserted-by":"publisher","first-page":"10284","DOI":"10.1073\/pnas.0900351106","article-title":"AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist","volume":"106","author":"Rhodes","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.7717\/peerj.8188\/ref-31","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40264-018-0644-4","article-title":"The risk for lung cancer incidence with calcium channel blockers: a systematic review and meta-analysis of observational studies","volume":"41","author":"Rotshild","year":"2018","journal-title":"Drug Safety"},{"key":"10.7717\/peerj.8188\/ref-32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41598-016-0023-2","article-title":"Impact of pneumonia and lung cancer on mortality of women with hypertension","volume":"6","author":"Shen","year":"2016","journal-title":"Scientific Reports"},{"key":"10.7717\/peerj.8188\/ref-33","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1186\/s12864-017-4223-3","article-title":"Genome-wide DNA methylation profiling reveals novel epigenetic signatures in squamous cell lung cancer","volume":"18","author":"Shi","year":"2017","journal-title":"BMC Genomics"},{"key":"10.7717\/peerj.8188\/ref-34","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","article-title":"Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials","volume":"11","author":"Sipahi","year":"2010","journal-title":"The Lancet Oncology"},{"key":"10.7717\/peerj.8188\/ref-35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.7717\/peerj.8188\/ref-36","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.cllc.2014.09.006","article-title":"Incidental receipt of cardiac medications and survival outcomes among patients with stage III non-small-cell lung cancer after definitive radiotherapy","volume":"16","author":"Wang","year":"2015","journal-title":"Clinical Lung Cancer"},{"key":"10.7717\/peerj.8188\/ref-37","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/j.ijcard.2012.05.096","article-title":"Long-term use of angiotensin II receptor blockers and risk of cancer: a population-based cohort analysis","volume":"167","author":"Wang","year":"2013","journal-title":"International Journal of Cardiology"},{"key":"10.7717\/peerj.8188\/ref-38","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1038\/s41418-019-0304-y","article-title":"Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA","volume":"26","author":"Wang","year":"2019","journal-title":"Cell Death and Differentiation"},{"key":"10.7717\/peerj.8188\/ref-39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/genes9010016","article-title":"SNCA is a functionally low-expressed gene in lung adenocarcinoma","volume":"9","author":"Yan","year":"2018","journal-title":"Gene"},{"key":"10.7717\/peerj.8188\/ref-40","first-page":"946","article-title":"Analysis of the correlation among hypertension, the intake of beta-blockers, and overall survival outcome in patients undergoing chemoradiotherapy with inoperable stage III non-small cell lung cancer","volume":"7","author":"Yang","year":"2017","journal-title":"American Journal of Cancer Research"},{"key":"10.7717\/peerj.8188\/ref-41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1759-7714.12490","article-title":"Risk factors of lymph node metastasis in patients with non-small cell lung cancer <\/= 2 cm in size: a monocentric population-based analysis","volume":"9","author":"Yu","year":"2018","journal-title":"Thoracic Cancer"},{"key":"10.7717\/peerj.8188\/ref-42","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1177\/1470320315607391","article-title":"Angiotensin receptor blockers use and the risk of lung cancer: a meta-analysis","volume":"16","author":"Zhang","year":"2015","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"key":"10.7717\/peerj.8188\/ref-43","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.12659\/msm.903312","article-title":"Angiotensin-converting enzyme gene deletion polymorphism is associated with lymph node metastasis in colorectal cancer patients in a chinese population","volume":"23","author":"Zheng","year":"2017","journal-title":"Medical Science Monitor"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/8188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/8188.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/8188.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/8188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T08:56:37Z","timestamp":1575968197000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/8188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,10]]},"references-count":43,"alternative-id":["10.7717\/peerj.8188"],"URL":"https:\/\/doi.org\/10.7717\/peerj.8188","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,10]]},"article-number":"e8188"}}